Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.

[1]  L. Kiemeney,et al.  Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. , 2013, Urologic oncology.

[2]  R. Dreicer,et al.  Intermittent Androgen Deprivation Therapy for Metastatic Prostate Cancer , 2013 .

[3]  J. Wolff,et al.  Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial , 2012, BJU international.

[4]  T. Tammela,et al.  The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. , 2012, The Journal of urology.

[5]  W. Dahut,et al.  An update on androgen deprivation therapy for prostate cancer. , 2010, Endocrine-related cancer.

[6]  P. Warde,et al.  Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. , 2010, The Journal of urology.

[7]  A. D'Amico,et al.  Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. , 2010, Circulation.

[8]  A. Bono,et al.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. , 2009, European urology.

[9]  Xianglin L. Du,et al.  Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer , 2009, Cancer.

[10]  P. Eskildsen,et al.  Fracture risk in Danish men with prostate cancer: a nationwide register study , 2007, BJU international.

[11]  M. Schonlau,et al.  Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer , 2007, Cancer.

[12]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Spry,et al.  Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. , 2006, European journal of cancer.

[14]  D. Nathan,et al.  Insulin sensitivity during combined androgen blockade for prostate cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[15]  G. Shenouda,et al.  Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer. , 2006, International journal of radiation oncology, biology, physics.

[16]  J. Nelson,et al.  Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[17]  J. Finkelstein,et al.  Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinoma , 2005, Cancer.

[18]  P. Walsh.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The Journal of urology.

[19]  N. Sato,et al.  Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. , 2004, Urology.

[20]  L. Collette,et al.  Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. , 2003, European urology.

[21]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[22]  L. Lenormand,et al.  Intermittent Androgen Suppression in the Treatment of Metastatic Prostate Cancer , 2000, European Urology.

[23]  P. Ditonno,et al.  Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Brown,et al.  The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.

[25]  M. Gleave,et al.  Intermittent androgen suppression for prostate cancer: rationale and clinical experience , 1998, Prostate Cancer and Prostatic Diseases.

[26]  M. Gleave,et al.  Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience , 1998, European Urology.

[27]  G. Oster,et al.  Health-related quality of life in patients with advanced prostate cancer: A multinational perspective , 1995, Quality of Life Research.

[28]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[29]  P. Fayers,et al.  Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Sandler,et al.  Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Terris,et al.  Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. , 2001, Urology.

[32]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.